GO:0042157 lipoprotein metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042157 lipoprotein metabolic process describes the chemical reactions and pathways involving conjugated, water-soluble proteins whose covalently attached nonprotein group consists of a lipid or lipids.
• Lipoproteins are macromolecular complexes that transport triglycerides, cholesterol, and other lipids through aqueous plasma, and their metabolism is central to cardiovascular and metabolic health.
• Key regulatory nodes include ANGPTL3, ANGPTL4, and ANGPTL8, which modulate lipoprotein lipase activity and plasma triglyceride levels.
• Endocytosis of lipoproteins via receptors such as the LDL receptor is a critical step in cellular lipid delivery and is implicated in atherosclerosis.
• TMEM41B functions as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis, linking membrane lipid dynamics to lipoprotein secretion.
• Dysregulation of lipoprotein metabolism underlies dyslipidemias, atherosclerosis, and cardiovascular disease, making it a major therapeutic target [3,4].
Description
Lipoprotein metabolic process (GO:0042157) encompasses the chemical reactions and pathways involving any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids. These processes are fundamental to the transport and distribution of hydrophobic lipids, including triglycerides and cholesterol, throughout the body. Lipoproteins are assembled in the liver and intestine, remodeled in the circulation, and taken up by peripheral tissues via receptor-mediated endocytosis. The regulation of lipoprotein metabolism is critical for maintaining lipid homeostasis, and its dysfunction is a hallmark of cardiovascular disease [1,3]. Researchers study this process to understand the molecular basis of dyslipidemias, to identify therapeutic targets, and to develop interventions that reduce cardiovascular risk [1,4].
lipoprotein metabolic process At A Glance
| GO ID | GO:0042157 |
|---|---|
| GO term | lipoprotein metabolic process |
| Ontology | biological_process |
| Synonym | lipoprotein metabolism |
| Major function | Transport and metabolism of lipids via water-soluble lipoprotein particles |
| Key regulators | ANGPTL3, ANGPTL4, ANGPTL8, TMEM41B, LDLR |
| Associated diseases | Atherosclerosis, dyslipidemia, cardiovascular disease |
| Research methods | CRISPR knockout, knock-in, overexpression, lipid profiling, endocytosis assays |
What Is GO:0042157?
GO:0042157 lipoprotein metabolic process is defined as the chemical reactions and pathways involving any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids. In simpler terms, it covers all the biochemical steps by which lipoproteins are synthesized, modified, and degraded, enabling the transport of lipids in the bloodstream.
Why Is lipoprotein metabolic process Important in Cell Biology?
Lipoprotein metabolism is essential for systemic lipid homeostasis, and its dysregulation is a primary driver of atherosclerosis and cardiovascular disease [3,4]. Understanding the molecular players, such as ANGPTL proteins and TMEM41B, provides opportunities for therapeutic intervention [1,2].
• Maintains cholesterol and triglyceride homeostasis in plasma and tissues.
• Dysregulation leads to hypertriglyceridemia and hypercholesterolemia.
• Central to the pathogenesis of atherosclerosis and coronary artery disease.
• Provides targets for lipid-lowering drugs, including ANGPTL3 inhibitors.
• Involves ER membrane dynamics via TMEM41B, linking lipid metabolism to organelle function.
• Receptor-mediated endocytosis of lipoproteins is critical for cellular lipid uptake.
• Lipoprotein-associated estrogens may influence cardiovascular risk.
• Bacterial lipoprotein transport systems offer models for studying lipid modification.
• Clinical management of dyslipidemias relies on understanding these pathways.
• Emerging CRISPR tools enable functional dissection of lipoprotein genes [1,2].
What Happens During lipoprotein metabolic process?
Lipoprotein Assembly and Secretion
In simple terms: The body builds lipoprotein particles in the liver and intestine to package fats for transport in the blood.
Lipoprotein biogenesis begins with the synthesis of apolipoproteins in the endoplasmic reticulum (ER), where they are lipidated to form nascent particles. TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis, facilitating the distribution of lipids across the ER membrane. These particles are then secreted into the circulation, where they undergo further remodeling.
Lipoprotein Lipolysis and Remodeling
In simple terms: Enzymes in the blood break down triglycerides carried by lipoproteins, releasing fatty acids for tissues.
Triglyceride-rich lipoproteins, such as chylomicrons and VLDL, are hydrolyzed by lipoprotein lipase (LPL) at the capillary endothelium, releasing free fatty acids for uptake by muscle and adipose tissue. This process is regulated by ANGPTL3, ANGPTL4, and ANGPTL8, which inhibit LPL under different metabolic conditions. Remodeling also involves exchange of apolipoproteins and lipids between lipoprotein classes.
Receptor-Mediated Endocytosis
In simple terms: Cells take up lipoproteins by binding them to receptors on the surface and pulling them inside.
Lipoproteins such as LDL are recognized by cell-surface receptors, including the LDL receptor (LDLR), and internalized via clathrin-mediated endocytosis. This delivers cholesterol and other lipids to cells and is tightly regulated by feedback mechanisms. Defects in this pathway lead to familial hypercholesterolemia and atherosclerosis.
Intracellular Lipid Trafficking and Storage
In simple terms: Once inside cells, lipoproteins are broken down and their lipids are used or stored.
After endocytosis, lipoproteins are delivered to lysosomes where cholesteryl esters are hydrolyzed to free cholesterol. Free cholesterol is then transported to the ER and other organelles, where it regulates cholesterol synthesis and esterification. Excess cholesterol can be stored as cholesteryl esters or exported via ABC transporters.
Regulation of Lipoprotein Metabolism
In simple terms: The body adjusts lipoprotein production and clearance based on nutritional and hormonal signals.
Lipoprotein metabolism is regulated at multiple levels, including transcriptional control of apolipoproteins and receptors, post-translational modification of enzymes, and hormonal signals such as insulin and estrogens [1,6]. ANGPTL proteins are key post-translational regulators that respond to feeding and fasting states. TMEM41B influences lipoprotein secretion through its role in ER lipid scrambling.
Key Genes Involved in GO:0042157 lipoprotein metabolic process
The following genes and proteins are central to lipoprotein metabolic process and are frequently studied in research and drug development.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANGPTL3 | Inhibits lipoprotein lipase and endothelial lipase | Target for lipid-lowering therapies |
| ANGPTL4 | Inhibits lipoprotein lipase in adipose and muscle | Regulates triglyceride uptake |
| ANGPTL8 | Regulates ANGPTL3 and ANGPTL4 activity | Modulates plasma triglyceride levels |
| TMEM41B | ER scramblase required for lipoprotein biogenesis | Links membrane dynamics to lipid homeostasis |
| LDLR | Mediates endocytosis of LDL particles | Defects cause familial hypercholesterolemia |
| APOB | Structural apolipoprotein of LDL and VLDL | Key component of atherogenic lipoproteins |
| APOA1 | Major apolipoprotein of HDL | Central to reverse cholesterol transport |
| LPL | Hydrolyzes triglycerides in chylomicrons and VLDL | Rate-limiting for plasma triglyceride clearance |
| CETP | Transfers cholesteryl esters between lipoproteins | Modulates HDL and LDL levels |
| PCSK9 | Promotes LDL receptor degradation | Target of lipid-lowering antibodies |
| ABCA1 | Mediates cholesterol efflux to apoA-I | Defects cause Tangier disease |
| ABCG1 | Mediates cholesterol efflux to HDL | Contributes to reverse cholesterol transport |
| SR-B1 | Mediates selective uptake of HDL cholesterol | Influences HDL metabolism |
| MTTP | Lipidates apoB for VLDL assembly | Required for lipoprotein secretion |
| APOC3 | Inhibits lipoprotein lipase and hepatic uptake | Target for triglyceride-lowering drugs |
| LIPC | Hepatic lipase, remodels HDL and IDL | Affects HDL and LDL levels |
| LCAT | Esterifies cholesterol on HDL | Essential for HDL maturation |
How Is lipoprotein metabolic process Regulated?
Lipoprotein metabolism is regulated by nutritional and hormonal signals. ANGPTL3, ANGPTL4, and ANGPTL8 are key post-translational regulators that inhibit lipoprotein lipase under different metabolic states, thereby controlling plasma triglyceride levels. TMEM41B regulates lipoprotein biogenesis through its ER scramblase activity, influencing lipid homeostasis. Additionally, lipoprotein-associated estrogens may modulate cardiovascular risk.
lipoprotein metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia | LDLR knockout hepatocytes |
| ANGPTL3 | Hypertriglyceridemia | ANGPTL3 knockout mouse |
| APOB | Atherosclerosis | APOB knock-in mouse |
| TMEM41B | Lipid homeostasis disorders | TMEM41B knockout cell lines |
| PCSK9 | Hypercholesterolemia | PCSK9 overexpression in liver |
Atherosclerosis and Cardiovascular Disease
Dysregulation of lipoprotein metabolism, particularly elevated LDL cholesterol and triglyceride-rich lipoproteins, is a major cause of atherosclerosis [3,4]. Endocytosis of lipoproteins and subsequent foam cell formation contribute to plaque development. Genetic variants in ANGPTL3, LDLR, and APOB influence cardiovascular risk [1,4].
Dyslipidemias
Monogenic and polygenic dyslipidemias result from mutations in genes such as LDLR, APOB, PCSK9, and ANGPTL3 [1,4]. These conditions lead to extreme plasma lipid levels and increased cardiovascular risk. Understanding lipoprotein metabolism is essential for diagnosis and treatment.
Metabolic Syndrome and Diabetes
Insulin resistance alters lipoprotein metabolism, leading to elevated triglycerides and low HDL. ANGPTL proteins are modulated by insulin, linking lipoprotein metabolism to glucose homeostasis. TMEM41B may also play a role in lipid homeostasis in metabolic tissues.
From lipoprotein metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate lipoprotein secretion? | Knockout cell line (e.g., hepatocytes) |
| Does mutation Y affect LDL uptake? | Point mutation knock-in in LDLR |
| Can overexpression of gene Z lower triglycerides? | Overexpression in mouse liver |
| How does gene A affect ER lipid scrambling? | Tagged knock-in for live imaging |
| What is the role of gene B in reverse cholesterol transport? | Knockout mouse model |
| Does gene C influence atherosclerosis progression? | ApoE knockout background |
How to Study the lipoprotein metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipid panel assay | Plasma cholesterol and triglycerides | Diagnosis of dyslipidemia |
| FPLC lipoprotein profiling | Lipoprotein size distribution | Characterization of mouse models |
| DiI-LDL uptake | Receptor-mediated endocytosis | LDLR functional studies |
| CRISPR knockout screen | Gene essentiality for lipid homeostasis | Discovery of novel regulators |
| Western blot | Protein expression of apolipoproteins | Validation of knockout/overexpression |
| qPCR | mRNA levels of lipoprotein genes | Transcriptional regulation studies |
| Immunofluorescence | Subcellular localization of lipoproteins | ER and Golgi trafficking |
| Lipoprotein lipase activity assay | Enzymatic hydrolysis of triglycerides | ANGPTL regulation studies |
Lipid Profiling and Lipoprotein Analysis
Plasma lipid levels and lipoprotein fractions are measured using enzymatic assays, ultracentrifugation, and NMR spectroscopy. These methods quantify cholesterol, triglycerides, and lipoprotein subclasses.
Cellular Uptake and Endocytosis Assays
Fluorescently labeled lipoproteins (e.g., DiI-LDL) are used to measure receptor-mediated endocytosis in cultured cells. This allows assessment of LDLR function and the impact of genetic variants.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes required for lipoprotein metabolism, such as TMEM41B. These screens link genotype to lipid phenotypes.
Animal Models and In Vivo Studies
Mouse models with targeted deletions or transgenic expression of lipoprotein genes are used to study systemic lipid metabolism and atherosclerosis [1,3]. These models are essential for preclinical drug testing.
How CRISPR Can Be Used to Study GO:0042157 lipoprotein metabolic process
Knockout
CRISPR knockout of genes such as ANGPTL3, TMEM41B, or LDLR in cell lines or animal models enables the study of their roles in lipoprotein metabolism [1,2,4]. Knockout hepatocytes can be used to assess lipoprotein secretion and lipid accumulation.
Point Mutation
Introducing disease-associated point mutations (e.g., in LDLR or APOB) via CRISPR base editing or homology-directed repair allows functional analysis of specific variants. These models help determine causality of genetic variants in dyslipidemia.
Knock-in
Knock-in of tagged versions of proteins (e.g., TMEM41B-GFP) facilitates live-cell imaging and proteomic studies. Knock-in of human APOB or ANGPTL3 into mouse models can humanize lipoprotein metabolism.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of genes like ANGPTL3 or PCSK9 can elevate plasma lipids and accelerate atherosclerosis in models [1,4]. Overexpression studies help identify therapeutic targets.
How EDITGENE Supports lipoprotein metabolic process Research
Researchers studying lipoprotein metabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid transport, lipoprotein assembly, or atherosclerosis. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for lipoprotein metabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| APOE Knockout HEK293 Cell Line | EDJ-KQ172 | Human | 348 | Details Get a Quote |
| APOA1 Knockout HEK293 Cell Line | EDJ-KQ1462 | Human | 335 | Details Get a Quote |
| PPARA Knockout HEK293 Cell Line | EDJ-KQ1808 | Human | 5465 | Details Get a Quote |
| APOL4 Knockout HEK293 Cell Line | EDJ-KQ2211 | Human | 80832 | Details Get a Quote |
| APOL3 Knockout HEK293 Cell Line | EDJ-KQ2922 | Human | 80833 | Details Get a Quote |
| APOL2 Knockout HEK293 Cell Line | EDJ-KQ2962 | Human | 23780 | Details Get a Quote |
| APOC3 Knockout HEK293 Cell Line | EDJ-KQ3340 | Human | 345 | Details Get a Quote |
| APOL5 Knockout HEK293 Cell Line | EDJ-KQ3444 | Human | 80831 | Details Get a Quote |
| APP Knockout HEK293 Cell Line | EDC09598 | Human | 351 | Details Get a Quote |
| MTTP Knockout HEK293 Cell Line | EDJ-KQ3757 | Human | 4547 | Details Get a Quote |
| NPC1L1 Knockout HEK293 Cell Line | EDJ-KQ3813 | Human | 29881 | Details Get a Quote |
| APOA2 Knockout HEK293 Cell Line | EDJ-KQ4066 | Human | 336 | Details Get a Quote |
| APOA4 Knockout HEK293 Cell Line | EDJ-KQ4067 | Human | 337 | Details Get a Quote |
| OLR1 Knockout HEK293 Cell Line | EDJ-KQ5382 | Human | 4973 | Details Get a Quote |
| APOL1 Knockout HEK293 Cell Line | EDJ-KQ6283 | Human | 8542 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About lipoprotein metabolic process
What is lipoprotein metabolic process?
It is the set of biochemical pathways involving conjugated, water-soluble proteins with covalently attached lipids, as defined by GO:0042157.
What genes are involved in lipoprotein metabolism?
Key genes include ANGPTL3, ANGPTL4, ANGPTL8, TMEM41B, LDLR, APOB, APOA1, LPL, and PCSK9 [1,2,3,4].
How is lipoprotein metabolism regulated?
It is regulated by ANGPTL proteins, TMEM41B, nutritional status, and hormones such as insulin and estrogens [1,2,6].
What diseases are linked to lipoprotein metabolism?
Atherosclerosis, dyslipidemias, cardiovascular disease, and metabolic syndrome [3,4].
What is the role of ANGPTL3 in lipoprotein metabolism?
ANGPTL3 inhibits lipoprotein lipase and endothelial lipase, increasing plasma triglycerides and cholesterol.
How does TMEM41B function in lipoprotein metabolism?
TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis.
What methods are used to study lipoprotein metabolism?
Lipid profiling, endocytosis assays, CRISPR screens, and animal models [2,3,4].
What is the LDL receptor's role?
LDLR mediates endocytosis of LDL particles, delivering cholesterol to cells.
Can CRISPR be used to study lipoprotein metabolism?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to dissect gene function [1,2,4].
What are the therapeutic targets in lipoprotein metabolism?
ANGPTL3, PCSK9, APOC3, and CETP are major targets for lipid-lowering therapies [1,4].
Conclusion
Lipoprotein metabolic process (GO:0042157) is a fundamental biological pathway that governs lipid transport and homeostasis. Its dysregulation is central to cardiovascular disease, and ongoing research continues to identify new regulatory mechanisms and therapeutic targets [1,2,3,4]. CRISPR-based models are invaluable for dissecting these pathways and translating findings into clinical applications.
References
- 1. Sylvers-Davie KL et al.. 2021. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.. Am J Physiol Endocrinol Metab 321(4):E493-E508 PMID: 34338039
- 2. Huang D et al.. 2021. TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis.. Cell Metab 33(8):1655-1670.e8 PMID: 34015269
- 3. Kockx M et al.. 2018. Triglyceride-Rich Lipoproteins.. Cardiol Clin 36(2):265-275 PMID: 29609756
- 4. Zanoni P et al.. 2018. Endocytosis of lipoproteins.. Atherosclerosis 275:273-295 PMID: 29980055
- 5. Illingworth DR. 1993. Lipoprotein metabolism.. Am J Kidney Dis 22(1):90-7 PMID: 8322800
- 6. Tikkanen MJ et al.. 2002. Lipoprotein-associated estrogens.. Cardiovasc Res 56(2):184-8 PMID: 12393088
